Jefferies analyst, Matthew Andrews, reiterated his Buy rating on shares of TherapeuticsMD (NASDAQ: TXMD) after hosting an investor visit of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE